CTAD 2022 – lecanemab data hold up, with a big but
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
Roche sets the gantenerumab expectations
Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.
Few safe havens surface in another down quarter for biopharma
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Lecanemab can; now the wait for details begins
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.